GCVRZ

Sanofi FR

• Reuters·9h ago

  Sanofi announces shareholder meeting

• Reuters·15h ago

  Nurix Therapeutics Q1 loss widens on higher costs

• Reuters·15h ago

  Shah Capital intends to vote against Novavax's board nominees, executive compensation

• Reuters·15h ago

  Nurix FY26 Q1 net loss widens 54.7% to $87.2 million; revenue drops to $6.3 million

• Reuters·1d ago

  Evotec nominates Dieter Weinand as supervisory board chairman successor

• Reuters·1d ago

  Sanofi says lunsekimig hits primary endpoints in phase 2 asthma trial

• Reuters·1d ago

  PRESS RELEASE: SANOFI’S LUNSEKIMIG MET PRIMARY AND KEY SECONDARY ENDPOINTS IN PHASE 2 RESPIRATORY STUDIES IN ASTHMA AND CRSWNP

• Reuters·04/02 01:04

  Thai Meiji Pharmaceutical launches Rezurock in Thailand for chronic graft-versus-host disease

• Reuters·04/01 12:00

  Aventis Energy files NI 43-101 technical report for Sting Copper project in Newfoundland and Labrador

• Reuters·03/31 05:00

  Sanofi says EU approves Rezurock for chronic graft-versus-host disease treatment

• Reuters·03/30 12:32

  Transcenta appoints Christopher Hwang head of global partnerships for HiCB platform

• Reuters·03/28 15:00

  Sanofi says phase 3 studies show amlitelimab improves atopic dermatitis at Week 24

• Reuters·03/27 12:01

  Sanofi; CHMP recommends EU approval for Sarclisa subcutaneous on-body injector in multiple myeloma

• Reuters·03/27 12:00

  SANOFI - RECOMMENDATION BASED ON POSITIVE RESULTS DEMONSTRATING COMPARABLE EFFICACY, PHARMACOKINETICS, AND SAFETY OF SARCLISA REGIMENS ADMINISTERED SUBCUTANEOUSLY COMPARED TO INTRAVENOUS INFUSION

• Reuters·03/26 08:32

  Sino Biopharmaceutical FY2025 proposes HKD 0.05 final dividend per share; revenue rises to CNY 31.8 billion